The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use of camizestrant over fulvestrant as well as discussing the next steps in the clinical development of camizestrant.
The abstract entitled ‘Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- What is camizestrant and what are its potential advantages over fulvestrant in the treatment of post-menopausal women with advanced ER-positive HER2-negative breast cancer? (0:18)
- What were the aims, design and eligibility criteria of the SERENA-2 trial? (1:18)
- What was the primary endpoint and how well was it achieved across the pre-specified subgroups of urgent medical need? (2:39)
- What were the safety and tolerability findings? (4:43)
- What will be the next steps in the clinical development of camizestrant? (5:43)
Disclosures: Mafalda Oliveira is a consultant for AstraZeneca, GuardantHealth, Roche, MSD, Relay Therapeutics, Pfizer, SeaGen, iTEOS and Gilead and discloses grant/research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, GSK, Novartis, PUMA Biotechnology, Roche, SeaGen and Zenith Epigenetics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
